Close Menu

NEW YORK – A team led by investigators at the Foundation for Research and Technology Hellas (FORTH) in Greece is moving ahead with plans to develop and validate a new point-of-care test for SARS-CoV-2, the virus that causes COVID-19, as well as other diseases.

The scientists received backing in the form of a €2.4 million ($2.8 million) EU grant this month and have founded a company, called Biopix-T, to commercialize the platform.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.